Table Info

Table 1.

Basic information included in the study

Study	Concomitant treatment	Q^※	Technology employed	Platform
Chen-2019 [9]	NA	7	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Liu-2012 [10]	NA	9	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Kang-2021 [11]	NA	9	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Wang-2022 [12]	NSAIDs: 100 (30/30)	7	ITS2-based DNA sequencing	Illumina Miseq sequencing platform
Yin-2021 [13]	NA	9	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Wang-2022 [14]	NSAIDs: 100 (62/62)	9	ITS2-based DNA sequencing	Illumina Miseq sequencing platform
Wang-2018 [15]	NA	6	NA	NA
Sun-2022 [16]	NA	8	ITS2-based DNA sequencing	Illumina Miseq sequencing platform
Qiao-2022 [17]	NA	3	ITS2-based DNA sequencing	Illumina Miseq sequencing platform
Breban-2017 [18]	NSAIDs: 35.3 (6/17); Corticosteroids: 82.4 (14/17); DMARDs: 53 (9/17); Biotherapy: 70.6 (12/17); Antiacid: 70.6 (12/17)	7	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Forbes-2018 [19]	NA	9	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Jeong-2019 [20]	NA	6	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Kishikawa-2020 [21]	csDMARDs: 28 (23/82); bDMARDs: 2 (2/82)	8	Metagenomic shotgun sequencing	Illumina high-throughput sequencing platform
Li-2021 [22]	NA	9	ITS2-based DNA sequencing	Illumina Miseq sequencing platform
Sun-2019 [23]	NA	7	ITS2-based DNA sequencing	Illumina Miseq sequencing platform
Wang-2022 [24]	NA	5	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Jin-2023 [25]	NA	8	16S rRNA gene sequencing	Illumina Miseq sequencing platform
Koh-2023 [26]	NA	8	16S rRNA gene sequencing	Illumina Miseq sequencing platform

^※ Quality (Q) of each study was based on the Newcastle-Ottawa Quality. NA: not applicable

Declarations

Acknowledgments

We would like to thank all the participants involved in this study.

Author contributions

QYS: Conceptualization, Investigation, Writing—review & editing. YZ: Data curation. DQ: Writing—original draft. XS and YS: Investigation, Data curation. RQL and SXZ: Data curation, Formal analysis, Validation. YFZ: Data curation. All the authors read and approved the final manuscript.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not appliable.

Consent to participate

Not appliable.

Consent to publication

Not appliable.

Availability of data and materials

The original data supporting the conclusions of this manuscript will be made available free of charge to any qualified researcher by the author, Sheng-Xiao Zhang, if required.

Funding

This study was supported by the Natural Science Foundation of Shanxi Province No. [202203021221269]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C. Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Front Immunol. 2021;12:686155. [DOI] [PubMed] [PMC]

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38. [DOI] [PubMed]

Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol. 2011;7:569–78. [DOI] [PubMed] [PMC]

Tung KS, Smith S, Matzner P, Kasai K, Oliver J, Feuchter F, et al. Murine autoimmune oophoritis, epididymoorchitis, and gastritis induced by day 3 thymectomy. Autoantibodies. Am J Pathol. 1987;126:303–14. [PubMed] [PMC]

Picchianti-Diamanti A, Panebianco C, Salemi S, Sorgi ML, Rosa RD, Tropea A, et al. Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept. Int J Mol Sci. 2018;19:2938. [DOI] [PubMed] [PMC]

Vaahtovuo J, Munukka E, Korkeamäki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol. 2008;35:1500–5. [PubMed]

Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21:895–905. [DOI] [PubMed]

Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013;2:e01202. [DOI] [PubMed] [PMC]

Chen M. Comparative Study of Gut Microbiota in Patients with Rheumatoid Arthritis and in Healthy Controls [dissertation]. Zunyi: Zunyi Medical University; 2019.

10.

Liu X, Wang Z, Wang Y, Li J, Zhang J, Zeng B, et al. Analysis of intestinal microbial community structure in patients with early rheuma-toid arthritis. J Third Mil Med Univ. 2012;34:2411–15. Chinese. [DOI]

11.

Kang H, Wu J, Zhang M, Wang Y. The distribution and clinical significance of intestinal flora in the pathogenesis of rheumatoid arthritis. Clin Educ Gen Pract. 2021;19:305. Chinese. [DOI]

12.

Wang ML, Li YY, Lei L, Sun WY, Chen AJ, Ming L. Characteristics of intestinal fungal flora in patients with rheumatoid arthritis. Chin J Microecol. 2022;34:944–7. Chinese. [DOI]

13.

Yin X, Zhang M, Zhang S, Wang J, Zhang Y, Li Y, et al. Study on the relationship between intestinal flora and peripheral cytokines in patients with rheumatoid arthritis. Zhonghua Fengshibingxue Zazhi. 2021;25. Chinese. [DOI]

14.

Wang M. Characteristics of Gut Fungal Microbiota in patients with rheumatoid arthritis based on ITS high-throughput sequencing [dissertation]. Dalian: Dalian Medical University; 2022. Chinese. [DOI]

15.

Wang Z. Gut microbiome in early rheumatoid arthritis patients. Tradit Chin Med Rehabil. 2018;9. Chinese. [DOI]

16.

Sun X, Wang Y, Li X, Wang M, Dong J, Tang W, et al. Alterations of gut fungal microbiota in patients with rheumatoid arthritis. PeerJ. 2022;10:e13037. [DOI] [PubMed] [PMC]

17.

Qiao J, Chang MJ, Zhang SX, Zhao R, Song S, Cheng T, et al. POS0556 Alteration of the gut microbiota in Chinese population with rheumatoid arthritis. Ann Rheum Dis. 2022;81:543.

18.

Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76:1614–22. [DOI] [PubMed]

19.

Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome. 2018;6:221. [DOI] [PubMed] [PMC]

20.

Jeong Y, Kim JW, You HJ, Park SJ, Lee J, Ju JH, et al. Gut Microbial Composition and Function Are Altered in Patients with Early Rheumatoid Arthritis. J Clin Med. 2019;8:693. [DOI] [PubMed] [PMC]

21.

Kishikawa T, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M, et al. Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis. 2020;79:103–11. [DOI] [PubMed] [PMC]

22.

Li Y, Zhang SX, Yin XF, Zhang MX, Qiao J, Xin XH, et al. The Gut Microbiota and Its Relevance to Peripheral Lymphocyte Subpopulations and Cytokines in Patients with Rheumatoid Arthritis. J Immunol Res. 2021;2021:6665563. [DOI] [PubMed] [PMC]

23.

Sun Y, Chen Q, Lin P, Xu R, He D, Ji W, et al. Characteristics of Gut Microbiota in Patients With Rheumatoid Arthritis in Shanghai, China. Front Cell Infect Microbiol. 2019;9:369. [DOI] [PubMed] [PMC]

24.

Wang Q, Zhang SX, Chang MJ, Qiao J, Wang CH, Li XF, et al. Characteristics of the Gut Microbiome and Its Relationship With Peripheral CD4⁺ T Cell Subpopulations and Cytokines in Rheumatoid Arthritis. Front Microbiol. 2022;13:799602. [DOI] [PubMed] [PMC]

25.

Jin J, Li J, Hou M, Ding X, Zhong Y, He J, et al. A Shifted Urinary Microbiota Associated with Disease Activity and Immune Responses in Rheumatoid Arthritis. Microbiol Spectr. 2023;11:e0366222. [DOI] [PubMed] [PMC]

26.

Koh JH, Lee EH, Cha KH, Pan CH, Kim D, Kim WU. Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responses. Arthritis Res Ther. 2023;25:32. [DOI] [PubMed] [PMC]

27.

Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017;18:2. [DOI] [PubMed] [PMC]

28.

Maeda Y, Takeda K. Host-microbiota interactions in rheumatoid arthritis. Exp Mol Med. 2019;51:1–6. [DOI] [PubMed] [PMC]

29.

Zhou D, Wang Q, Liu H. Coronavirus disease 2019 and the gut-lung axis. Int J Infect Dis. 2021;113:300–7. [DOI] [PubMed] [PMC]

30.

Zhao X, Chen Y, Wen W, Cheng Y, Li R, Liu Y, et al. Identification of lipopolysaccharide-binding protein as a novel citrullinated autoantigen in rheumatoid arthritis. Rheumatol Autoimmun. 2022;2:5–14. [DOI]

31.

Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122:107–18. [DOI] [PubMed]

32.

Spurlock CF 3rd, Gass HM 4th, Bryant CJ, Wells BC, Olsen NJ, Aune TM. Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes. Rheumatology (Oxford). 2015;54:178–87. [DOI] [PubMed] [PMC]

33.

Sayers E, MacGregor A, Carding SR. Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis. AIMS Microbiol. 2018;4:642–54. [DOI] [PubMed] [PMC]

34.

Zhou B, Xia X, Wang P, Chen S, Yu C, Huang R, et al. Induction and Amelioration of Methotrexate-Induced Gastrointestinal Toxicity are Related to Immune Response and Gut Microbiota. EBioMedicine. 2018;33:122–33. [DOI] [PubMed] [PMC]

35.

Liu X, Pan X, Liu H, Ma X. Gut Microbial Diversity in Female Patients With Invasive Mole and Choriocarcinoma and Its Differences Versus Healthy Controls. Front Cell Infect Microbiol. 2021;11:704100. [DOI] [PubMed] [PMC]

36.

Malaguarnera L. Vitamin D and microbiota: Two sides of the same coin in the immunomodulatory aspects. Int Immunopharmacol. 2020;79:106112. [DOI] [PubMed]

37.

Yamamoto EA, Jørgensen TN. Relationships Between Vitamin D, Gut Microbiome, and Systemic Autoimmunity. Front Immunol. 2020;10:3141. [DOI] [PubMed] [PMC]

38.

Murdaca G, Gerosa A, Paladin F, Petrocchi L, Banchero S, Gangemi S. Vitamin D and Microbiota: Is There a Link with Allergies? Int J Mol Sci. 2021;22:4288. [DOI] [PubMed] [PMC]

39.

Gupta VK, Cunningham KY, Hur B, Bakshi U, Huang H, Warrington KJ, et al. Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis. Genome Med. 2021;13:149. [DOI] [PubMed] [PMC]